MediPharm Labs Corp.
LABS.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 23.53% | -44.34% | 89.93% | 39.81% | 36.96% |
| Total Depreciation and Amortization | -19.72% | -43.32% | -49.47% | -23.95% | -17.43% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -73.16% | -62.65% | -57.50% | -264.18% | 186.93% |
| Change in Net Operating Assets | 54.53% | 146.79% | -704.44% | -74.39% | -32.97% |
| Cash from Operations | 76.37% | -70.51% | -85.41% | -170.35% | 79.86% |
| Capital Expenditure | 52.07% | 25.67% | -87.82% | 64.11% | 87.51% |
| Sale of Property, Plant, and Equipment | -- | 19,952.94% | -- | -100.00% | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 1,477.27% | 11,966.41% | -107.52% | -100.99% | -101.98% |
| Total Debt Issued | -100.00% | -33.24% | -- | -- | -- |
| Total Debt Repaid | 94.76% | 45.10% | 1.49% | 13.81% | -490.72% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 135.00% | -65.17% | -72.41% | -47.33% | -77.53% |
| Cash from Financing | 96.75% | -35.46% | -197.14% | 1.58% | -630.87% |
| Foreign Exchange rate Adjustments | -133.33% | 79.74% | 24.72% | 91.04% | -81.56% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 107.58% | 302.99% | -189.12% | -127.08% | -59.09% |